Everyone is going crazy about this article I wrote on Cellectis. I've got comments from people telling me to mortgage my house and park a truck-load of money into this company. Calm down everyone. Cellectis is years away from and kind of FDA approval of their UCAR T-cell therapy. There's plenty of time to be calm and not chase this stock higher.
Novartis is going to be the first company to get FDA approval on a CAR T therapy. The actual FDA approval is likely to come by October 2017. Novartis is running with the lead CAR T therapy pack in this exciting new medicine that opens up a whole new way of battling cancer.